Jedd Wolchok

Biography

 Jedd Wolchok received his undergraduate degree from Princeton University and both M.D and Ph.D. from New York University, where he also fulfilled his residency program.  He completed his fellowship at MSK and remained on faculty with an appointment in the Melanoma Immunotherapeutics Service. Jedd Wolchok, MD, PhD is the Lloyd J. Old and Daniel K. Ludwig Chair in Clinical Investigation, Chief of the Melanoma and Immunotherapeutics Service, Director of the Parker Institute for Cancer Immunotherapy at Memorial Sloan Kettering Cancer Center with an expertise in the treatment of metastatic melanoma. He has been at the forefront of cancer immunotherapy, as an active clinician scientist exploring immunotherapy and as a principal investigator in several pivotal clinical trials, including the phase III trial that led to the FDA approval of ipilimumab + nivolumab as a treatment for patients with advanced melanoma.

Research Interest

 Jedd Wolchok received his undergraduate degree from Princeton University and both M.D and Ph.D. from New York University, where he also fulfilled his residency program.  He completed his fellowship at MSK and remained on faculty with an appointment in the Melanoma Immunotherapeutics Service. Jedd Wolchok, MD, PhD is the Lloyd J. Old and Daniel K. Ludwig Chair in Clinical Investigation, Chief of the Melanoma and Immunotherapeutics Service, Director of the Parker Institute for Cancer Immunotherapy at Memorial Sloan Kettering Cancer Center with an expertise in the treatment of metastatic melanoma. He has been at the forefront of cancer immunotherapy, as an active clinician scientist exploring immunotherapy and as a principal investigator in several pivotal clinical trials, including the phase III trial that led to the FDA approval of ipilimumab + nivolumab as a treatment for patients with advanced melanoma.